nach oben

Zeitschrift für Rheumatologie

Erschienen in:

16.05.2019 | Zielgerichtete Therapie | Leitthema

Neue Substanzen zur Therapie der juvenilen idiopathischen Arthritis

verfasst von: Prof. Dr. Gerd Horneff

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Einführung der Biologika vor 20 Jahren hat die Pharmakotherapie der juvenilen idiopathischen Arthritis wesentlich gewandelt. Biologika zählen zu den erfolgreichsten Innovationen nicht nur in der Rheumatologie und bieten neben einem raschen Wirkeintritt und einer starken Wirksamkeit auch eine Option zur Prävention von Langzeitschäden und die realistische Aussicht auf eine Remission. Auf Innovationen bei den Biologika und die Bedeutung der neuesten Gruppe zur „targeted therapy“ mit „small molecules“ in der Kinderrheumatologie wird in diesem Beitrag eingegangen.

Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342(11):763–769CrossRef

Lovell DJ, Ruperto N, Goodman S et al (2008) Pediatric rheumatology collaborative study group; pediatric rheumatology international trials Organisation. Adalimumab with or without Methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810–820CrossRef

Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-Pérez N, Keltsev V, Kingsbury DJ, Del Rocio Maldonado Velázquez M, Nikishina I, Silverman ED, Joos R, Smolewska E, Bandeira M, Minden K, van Royen-Kerkhof A, Emminger W, Foeldvari I, Lauwerys BR, Sztajnbok F, Gilmer KE, Xu Z, Leu JH, Kim L, Lamberth SL, Loza MJ, Lovell DJ, Martini A, Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG) (2017) Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis 77(1):21–29. https://doi.org/10.1136/annrheumdis-2016-210456 CrossRefPubMedPubMedCentral

Brunner HI, Ruperto N, Keltsev V, Alexeeva E, Abud-Mendoza C, Schmeling H, Maldonado-Velázquez MDR, Rubio-Pérez N, Stanislav M, Chasnyk V, Brown D, Henrickson M, Kingsbury D, Rabinovich CE, Zeft A, Silverman E, Wang M, Charlton P, Lledo-Garcia R, Shaughnessy L, Lovell DJ, Martini A (2016) A multi-center, open-label study to assess the Pharmacokinetics, efficacy and safety of Certolizumab pegol in children and adolescents with moderately to severely active Polyarticular-course juvenile idiopathic arthritis: week 24 results [abstract]. Arthritis Rheumatol 68(suppl 10):

Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW, SYCAMORE Study Group. (2017) Adalimumab plus methotrexate for Uveitis in juvenile idiopathic arthritis. N Engl J Med 376(17):1637–1164CrossRef

Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain P‑D et al (2017) Efficacy and safety of adalimumab every other week versus methotrexate in pediatric patients with severe chronic plaque psoriasis: A randomized, double-blind phase 3 study. Lancet 390(10089):40–49CrossRef

Horneff G, Seyger MMB, Arikan D et al (2018) Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn’s disease. J Pediatr 201:166–175.e3CrossRef

Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, Zhang J, Curtis JR (2016) The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther 18(1):210CrossRef

Becker I, Horneff G (2017) Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German biologics in pediatric rheumatology registry. Arthritis Care Res (Hoboken) 69(4):552–556CrossRef

10.

Horneff G (2015) Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf 14:1111–1126CrossRef

11.

Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:1263–1271CrossRef

12.

Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T (2011) Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology 50(1):230–236CrossRef

13.

Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K (2016) A Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry. Clin Exp Rheumatol 34(6):1113–1120PubMed

14.

Smith RJ, Chin JE, Sam LM, Justen JM (1991) Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 34(1):78–83CrossRef

15.

DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML, Angeles-Han S, Milojevic D, Schikler KN, Vehe RK, Weiss JE, Weiss P, Ilowite NT, Wallace CA (2012) Juvenile idiopathic arthritis disease-specific research committee of childhood arthritis rheumatology and research alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 64(7):1001–1010

16.

Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, Rieber N, Hufnagel M, Jansson AF, Hedrich C, Winowski H, Berger T, Foeldvari I, Ganser G, Hospach A, Huppertz HI, Mönkemöller K, Neudorf U, Weißbarth-Riedel E, Wittkowski H, Horneff G, Foell D (2018) PRO-KIND SJIA project collaborators. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J 16(1):7CrossRef

17.

Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ, PRINTO, PRCSG (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367(25):2396–2406CrossRef

18.

Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ, Paediatric Rheumatology International Trials Organisation, Pediatric Rheumatology Collaborative Study Group (PRCSG) (2018) Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5‑year long-term extension of the phase III pivotal trials. Ann Rheum Dis 77(12):1710–1719CrossRef

19.

Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, Wulffraat NM (2014) Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 66(4):1034–1043CrossRef

20.

Horneff G, Schulz AC, Klein A, Eising K (2018) Anakinra for first line steroid free treatment in systemic onset juvenile arthritis. EULAR18-2161. Ann Rheum Dis 77(Suppl):A482

21.

Horneff G, Peitz J, Kekow J, Foell D (2017) Canakinumab for first line steroid-free treatment in a child with systemic-onset juvenile idiopathic arthritis. Scand J Rheumatol 46(6):500–501CrossRef

22.

Kimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic PA, Mieszkalski K, Graham TB, Ibarra M, Ilowite N, Klein-Gitelman M, Onel K, Prahalad S, Punaro M, Ringold S, Toib D, Van Mater H, Weiss JE, Weiss PF, Schanberg LE, Registry Investigators CARRA (2017) Pilot study comparing the childhood arthritis & rheumatology research alliance (CARRA) systemic juvenile idiopathic arthritis consensus treatment plans. Pediatr Rheumatol Online J 15(1):23CrossRef

23.

De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A, PRINTO, PRCSG (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367(25):2385–2395CrossRef

24.

Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Pérez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gámir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F, Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG) (2014) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74(6):1110–1117. https://doi.org/10.1136/annrheumdis-2014-205351

25.

Genovese MC, Fleischmann R, Kivitz AJ et al (2015) Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol 67:1424–1437CrossRef

26.

Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 76(5):840–847. https://doi.org/10.1136/annrheumdis-2016-210310 CrossRefPubMed

27.

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S, FUTURE 2 Study Group (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386(9999):1137–1146CrossRef

28.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group, FIXTURE Study Group (2014) Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 371(4):326–338CrossRef

29.

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group (2016) Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 375(4):345–356CrossRef

30.

Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A (2016) A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 175(2):273–286CrossRef

31.

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 study investigators (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675–1684CrossRef

32.

Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664):633–640. https://doi.org/10.1016/S0140-6736(09)60140-9 (Erratum in: Lancet. 2009 Apr 18;373(9672):1340. Lancet. 2010 Nov 6;376(9752):1542)CrossRefPubMed

33.

Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P, Ustekinumab Crohn’s Disease Study Group (2008) A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 135(4):1130–1141CrossRef

34.

Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ (2018) Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis 77(9):1295–1302CrossRef

35.

Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH, Paediatric Rheumatology INternational Trials Organization Pediatric Rheumatology Collaborative Study Group (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383–391CrossRef

36.

Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Berman A, Calvo Penadés I, Antón J, Ávila-Zapata F, Cuttica R, Horneff G, Foeldvari I, Keltsev V, Kingsbury DJ, Viola DO, Joos R, Lauwerys B, Gastañaga PME, Rama ME, Wouters C, Bohnsack J, Breedt J, Fischbach M, Lutz T, Minden K, Miraval T, Ally MMTM, Rubio-Pérez N, Solau Gervais E, van Zyl R, Li X, Nys M, Wong R, Banerjee S, Lovell DJ, Martini A, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG) (2018) Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study. Arthritis Rheumatol 70(7):1144–1154CrossRef

37.

Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A (2018) Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature. Curr Drug Saf 13(3):150–164CrossRef

38.

Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R (2018) A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Semin Arthritis Rheum 48(3):406–415. https://doi.org/10.1016/j.semarthrit.2018.07.006 CrossRefPubMed

39.

He Y, Wong AY, Chan EW, Lau WC, Man KK, Chui CS, Worsley AJ, Wong IC (2013) BMC Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Musculoskelet Disord 14:298. https://doi.org/10.1186/1471-2474-14-298 CrossRef

40.

Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S (2016) Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol 74(5):841–850. https://doi.org/10.1016/j.jaad.2016.01.013 CrossRefPubMed

41.

Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, Horneff G, Smolewska E, Vehe RK, Hazra A, Wang R, Mebus CA, Alvey C, Lamba M, Krishnaswami S, Stock TC, Wang M, Suehiro R, Martini A, Lovell DJ, Pediatric Rheumatology International Trials Organization (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG) (2017) Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J 15(1):86. https://doi.org/10.1186/s12969-017-0212-y CrossRefPubMedPubMedCentral

42.

Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, Montealegre Sanchez GA, de Jesus AA, Huang Y, Tsai WL, Gadina M, Prakash A, Janes JM, Zhang X, Macias WL, Kumar P, Goldbach-Mansky R (2018) Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther 104(2):364–373CrossRef

43.

Riese RJ, Krishnaswami S, Kremer J (2010) Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 24:513–526CrossRef

44.

Wells AF, Edwards CJ, Kivitz AJ, Bird P, Nguyen D, Paris M, Teng L, Aelion JA (2018) Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology. https://doi.org/10.1093/rheumatology/key032. [Epub ahead of print]CrossRefPubMed

Titel: Neue Substanzen zur Therapie der juvenilen idiopathischen Arthritis
verfasst von: Prof. Dr. Gerd Horneff
Publikationsdatum: 16.05.2019
Verlag: Springer Medizin
Schlagwörter: Zielgerichtete Therapie
Juvenile idiopathische Arthritis
Juvenile idiopathische Arthritis
Adalimumab
Tocilizumab
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 7/2019
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-019-0646-3

Passend zum Thema

AGO-Leitlinie 2024: Update zu CDK4 & 6 Inhibitoren

Die Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) hat am 02. März 2024 ihre aktualisierten Empfehlungen präsentiert.[1,2] Welchen Stellenwert CDK4 & 6 Inhibitoren in der Therapie des Hormonrezeptor-positiven (HR+), HER2-negativen (HER2-) Mammakarzinoms haben, erfahren Sie hier im Update.

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

In der MONARCH-3-Studie erhielten Patientinnen mit fortgeschrittenem HR+, HER2- Brustkrebs Abemaciclib [1,a] in Kombination mit nicht-steroidalem Aromatasehemmer (nsAI). Die finalen Daten bestätigen den in früheren Analysen beobachteten Unterschied zugunsten der Kombinationstherapie. [2] Details dazu vom SABCS 2023.

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom

Es erwarten Sie praxisrelevante Patientenfälle, kompakte Studiendarstellungen, informative Experteninterviews sowie weitere spannende Inhalte rund um das HR+, HER2- Mammakarzinom.

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

So bestimmen Sie die Knochendichte bei Kindern

Juvenile Dermatomyositis – was gibt es Neues?

Osteologie, Physikalische Medizin

MTX-Intoleranz bei Kindern und Jugendlichen mit juveniler idiopathischer Arthritis

Depressive Symptomatik bei früher rheumatoider Arthritis

Neue Therapiewege, bessere Outcomes?

Passend zum Thema

AGO-Leitlinie 2024: Update zu CDK4 & 6 Inhibitoren

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom